Abstract Multiple sclerosis (MS) is a common demyelinating neurodegenerative disease with a strong genetic component. Previous studies have associated genetic variants in IL2RA and IL7R in the pathophysiology of the disease. In this study, we describe the association between IL2RA
Introduction
Multiple sclerosis (MS) is one of the most prevalent diseases of the central nervous system, affecting over two million people worldwide [1] . MS is a chronic inflammatory disease characterized by myelin loss, varying degrees of axonal pathology, and progressive neurological dysfunction [2, 3] ; the symptoms vary widely and may affect vision, hearing, cognition, balance, and movement.
Genetic susceptibility factors resulting in an increased predisposition to developing MS are known to exist, with the human leucocyte antigen (HLA)-DRB1 region providing the strongest risk; however, additional risk factors have been described [4, 5] . Outside of the HLA region, interleukin 2 receptor alpha (IL2RA) and interleukin 7 receptor (IL7R) are two of the genes more consistently found associated with the risk of MS [6, 7] . A meta-analysis of IL2RA rs2104286 and IL7R rs6897932 has confirmed these associations in the Caucasian population [8, 9] , including Canadian patients [10] . Interestingly, one study found IL7R rs6897932 to be exclusively associated with patients presenting primary progressive MS (PPMS) and secondary progressive MS (SPMS), suggesting IL7R may have an effect on the development of a progressive disease course [11] .
To further elucidate the role of IL2RA and IL7R in MS pathogenesis and disease course, we genotyped rs2104286 and rs6897932 in a large Canadian case-control series consisting of 1,978 MS patients and 830 controls and sequenced the entire coding region for each gene in 95 MS patients.
Materials and methods
Genetic analysis of IL2RA and IL7R was performed in MS patients and unrelated healthy controls collected through the longitudinal Canadian Collaborative Project on the Genetic Susceptibility to Multiple Sclerosis (CCPGSMS) between 1997 and 2008 [12] . The ethical review boards at the University of British Columbia approved the study, and all participants provided informed consent. All patients were diagnosed with MS according to Poser criteria prior to 2001 [13] or McDonald criteria thereafter [14, 15] . A total of 1,978 MS patients and 830 controls were characterized in this study. The mean age at blood collection was 46.7 years (SD ±11.7) for MS patients and 66.9 years (SD ±9.7) for controls, with a male to female ratio of 1:2.77 and 1:0.97, respectively. The mean age at MS onset was 30.9 years (SD ±9.7), with a median Expanded Disability Status Scale (EDSS) score of 3.5 and an average of 4.0 (SD ±2.6) [16] . Detailed clinical course was available for 1,632 patients (82.5 %); the majority presented a clinical course consistent with relapsing remitting MS (RRMS) (54.6 %), and the remainder presented PPMS (25.0 %) or SPMS (20.4 %). A positive family history of disease, defined as having at least one first-or second-degree relative also diagnosed with MS, was present in 82.5 % of cases. The higher than usual frequency of patients with a family history of disease, and as a consequence the increased number of patients with PPMS, is the result of our research protocol which favored the collection of familial probands.
IL2RA rs2104286 and IL7R rs6897932 were genotyped on an ABI 7900 using TaqMan probes and analyzed with SDS 2.4 software. Genotypic associations were examined by chisquare test. Bonferroni correction for multiple testing was applied, and p values <0.005 are considered significant after adjustment for ten independent tests (two variants in five disease groups). All SNPs were consistent with Hardy-Weinberg equilibrium (p value >0.05).
Primer pairs were designed for specific amplicons containing all coding exons and exon-intron boundaries for IL2RA and IL7R (sequences available on request). PCR products were generated using standard protocols. Magnetic beadbased PCR purification was achieved with Agencourt technology. Sequencing products were analyzed on an ABI 3730xl capillary array and SeqScape software as previously described [17] .
Results

Power analysis
A priori power analysis assuming a disease prevalence of 0.001 [1] with a minor allele frequency of 0.25, as observed in Caucasian populations, and the previously described relative risk of 1.25 [8, 9] indicated that our series (n=2,808) has a 93 % probability of identifying nominally significant differences in genotype frequencies between MS patients and controls. Analysis of MS subgroups, assuming the same parameters, indicated a statistical power of 91 % for familial MS, 59 % for sporadic MS, 83 % for RRMS, and 79 % for progressive MS (PrMS; PPMS and SPMS).
Interleukin 2 receptor alpha
Association analysis of IL2RA rs2104286 in our Canadian MS series consisting of 1,978 patients and 830 controls showed no significant differences in genotype or allelic frequencies between cases and controls (Table 1) . Although significant associations were not identified, carriers of the rs2104286 G allele presented a protective odds ratio (OR) of 0.87 (95 % CI=0.74-1.03) (Fig. 1) , similar to those previously reported [8, 7] . To further characterize the role of IL2RA in MS, we performed stratified association analyses according to family history of disease as well as disease progression. Differences in rs2104286 genotypic or allelic frequencies were not observed between healthy controls and patients with positive family history of disease or progressive disease (Table 1) . However, a trend towards association for IL2RA genotypes was identified in MS patients without a family history of disease (p value=0.05, OR=0.77; 95 % CI=0.60-1.00) and, to a lesser extent, in patients with a disease course consistent with RRMS (p value=0.05, OR=0.86; 95 % CI=0.71-1.05) (Fig. 1) .
In an attempt to identify the biologically relevant variants affecting MS risk, we sequenced the entire coding region of IL2RA in 95 randomly selected patients without a family history of disease. Sequencing analysis identified two silent and two missense variants ( Table 2 ). All four variants had been previously reported and did not present an allelic frequency sufficiently distinct from the general population to account for the difference in disease risk observed in this group.
Interleukin 7 receptor
Genotyping of rs6897932 in MS cases and controls did not result in a statistically significant association between genotypic or allelic frequencies and risk of MS (p value=0.07) ( Table 1 ) although a trend towards association, with a protective OR of 0.87 (95 % CI=0.74-1.02) for TT/CT vs CC genotypes, was observed (Fig. 1) . Analysis in MS patients stratified by family history of disease did not result in a significant association, with ORs for familial and sporadic patients similar to those obtained for the entire cohort. Similarly, stratified analysis for disease course did not reveal a significant association between IL7R and patients presenting RRMS; however, a statistically significant association was observed between patients diagnosed with PrMS and rs6897932 genotype (p value = 0.002) ( Table 1) . This association appears to be primarily driven by those patients suffering from PPMS (p value=0.001, OR=0.68; 95 % CI=0.53-0.86) as those with SPMS are not significantly different from healthy controls (p value=0.06, OR=0.80; 95 % CI=0.62-1.03).
The associated rs6897932 C to T transition results in a threonine to isoleucine substitution at position 244 (p.T244I). In vitro studies have shown increased skipping of ILR7 exon 6 when the C allele is present, thus potentially altering the ratio between membrane-bound and soluble protein [6] . To investigate whether other biologically relevant variants in IL7R could account for the observed associations, we sequenced its entire coding region in 95 randomly selected MS probands. This analysis identified two silent and seven missense variants, including p.T244I ( Table 2 ). The minor allele frequency (MAF) for the identified variants was relatively similar to those previously reported, with the largest difference in allelic frequency being observed for p.T244I and p.I356V with an 8 % decrease and 9 % increase, respectively.
Discussion
The implementation of ever larger genome-wide association studies of MS has nominated a myriad of variants with a potential role in disease susceptibility; amongst those, variants located within the HLA system appear to account for the largest effect on disease risk [4] . Two of the non-HLA variants which have been substantially replicated in independent studies, albeit not consistently, are the rs2104286 in IL2RA and rs6897932 in IL7R [8, 9] . These two genes are plausible biological candidates for MS since the proteins they encode, interleukin 2 receptor alpha (IL2Rα, also known as CD25) and interleukin 7 receptor alpha (IL7Rα, also known as CD127), play a fundamental role in lymphocyte development and the modulation of T cell effector function [18, 19] . The goal of this study is to further define the role of IL2RA rs2104286 and IL7R rs6897932 in the susceptibility to MS. To this end, we characterized these two variants in a case-control series of MS patients from Canada. This cohort is noticeably distinct from those described in most association studies of IL2RA and IL7R with MS [8, 9] as it contains a higher proportion of patients with a family history of disease (82.5 %) as well as a higher number of patients presenting PPMS (25 %). Interestingly, neither variant resulted in a significant association with disease in the entire cohort (Table 1) despite having a 93 % power of detection. Although not significantly associated, the minor allele for both variants presented a clear trend towards a protective effect as previously described (Fig. 1) .
Stratified analysis for IL2RA indicates that the trend towards association is driven by the patients without a family history of disease, thus suggesting that genetic components for familial and sporadic disease may be somewhat distinct. This is not unexpected if we assume that sporadic disease is caused by the accumulation of genetic and environmental variants of small individual effect, whereas the onset of disease for familial forms is determined by only a few variants of stronger effect [20] . In this scenario, the small difference in disease risk resulting from genetic variants in IL2RA (OR=0.77) is likely to have a more profound outcome on sporadic patients, as the accumulation of variants of small effects is necessary to reach a minimum risk threshold for the onset of MS. In contrast, the influence of variants of small effect in patients with a family history of disease will likely be minor on the overall disease risk, if a few variants of strong effect are already present. Sequencing of IL2RA in MS patients without family history of disease did not identify coding variants that could account for the observed association, thus suggesting that the effect on MS risk is unlikely to be driven by amino acid substitutions.
Similarly, the association of IL7R with MS resulted in a nonsignificant trend in the entire cohort; however, analysis of clinical subtypes identified a strong association between rs6897932 and patients presenting PrMS (Table 1) . Our study replicates previous reports of association between IL7R variants with PrMS, emphasizing the existence of specific genetic components implicated in the development of progressive disease [11, 21] . Sequencing of IL7R in MS patients identified two missense variants (rs6897932, p.T244I, and rs3194051, p.I356V) with an allelic frequency difference greater than 8 % from those expected in the general population ( Table 2 ). The p.T244I variant, genotyped in this study, has been shown to affect the alternative splicing of IL7R exon 6 and alter the amounts of soluble and membrane-bound protein, thus suggesting a possible mechanism for disease [6, 21] . In contrast, no functional outcome has been described for p.I356V, and association studies for this variant (rs3194051) have provided conflicting results, with some studies reporting a significant association with the risk of MS [22] [23] [24] that others could not replicate [6, 25] .
In summary, our study has confirmed the association between genetic variants in IL2RA and IL7R in MS and further defined this association to specific disease subtypes. Our data suggest that the major genetic components in sporadic and familial MS are distinct, with common variants of small effect being critical for sporadic disease and a small number of variants of greater effect for familial MS. In addition, we have replicated the association of IL7R rs6897932 in patients with PrMS, reinforcing the notion that the absence of remission seen in PPMS patients may be the result of a decrease in soluble IL7Rα in regulatory T cells [21, 26] , thus providing a mechanistic target for therapeutic intervention.
